Pathophysiology and biochemical mechanisms involved in MPTP-induced parkinsonism.
D015632:1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; D015655:1-Methyl-4-phenylpyridinium; D000818:Animals; D001921:Brain / Q000378:metabolism / Q000473:pathology; D004195:Disease Models, Animal; D004298:Dopamine / Q000378:metabolism; D000882:Haplorhini; D051379:Mice; D008995:Monoamine Oxidase / Q000378:metabolism; D009498:Neurotoxins / Q000378:metabolism; D010302:Parkinson Disease, Secondary / Q000378:metabolism* / Q000473:pathology / Q000503:physiopathology; D011725:Pyridines / Q000378:metabolism / Q000633:toxicity*; D011726:Pyridinium Compounds / Q000378:metabolism; D013116:Spinal Cord / Q000378:metabolism / Q000473:pathology
D009498:Neurotoxins; D011725:Pyridines; D011726:Pyridinium Compounds; D015632:1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; D008995:Monoamine Oxidase; D015655:1-Methyl-4-phenylpyridinium; D004298:Dopamine